[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 6 sources · 4 days · First seen · Last updated

Yuhan Corporation oncology drug developments

Overview

Yuhan Corporation has achieved recognition for its lung cancer treatment, Leclaza (lazertinib), which was named the Best Pharmaceutical Product at the inaugural Prix Galien Korea awards. Leclaza, a third-generation EGFR tyrosine kinase inhibitor, was developed through an open R&D model and has expanded into global markets following US FDA approval as a combination therapy.

Building on its oncology portfolio, the company is also advancing YH42946, an oral HER2-targeted therapy candidate. Presented at the 2026 World Conference on Lung Cancer, YH42946 is designed to target HER2 mutations and EGFR exon 20 insertion mutations. The drug is currently in a Phase 1/2 clinical trial evaluating its safety and anti-tumor effects in patients with solid tumors, with preliminary results expected by the end of 2026.

Entities

Yuhan Corporation · Johnson & Johnson · Prix Galien Korea · World Conference on Lung Cancer · Yonsei University

Timeline

  1. 12 days ago

    [HEALTH] 2 sources
    Yuhan Corporation presents clinical progress for HER2-targeted cancer drug YH42946

    Yuhan Corporation shared progress on its oral HER2-targeted cancer drug YH42946 at the WCLC, targeting solid tumors and brain metastases with clinical results expected by late 2026.

  2. 15 days ago

    [BUSINESS] 5 sources
    Yuhan Corporation’s Leclaza wins Best Pharmaceutical Product award

    Yuhan Corporation’s lung cancer drug Leclaza won the Best Pharmaceutical Product award at the first Prix Galien Korea, following its recent US FDA approval.

Sources

biotimes.co.kr · bokuennews.com · bosa.co.kr · hin.company · localsegye.co.kr · thebionews.net